We support patients across the entire kidney care journey including prevention, transition, treatment and transplant.
33,600+ people participated in a Kidney Smart® class in 2022, another record-setting year of engagement for the no-cost kidney disease education program
In 2022, over 15% of our patients dialyzed in the comfort and convenience of home. * We expanded our home dialysis care program to include new technologies to enhance patient and physician experience. Peritoneal dialysis (PD) and home hemodialysis (HHD) patients increasingly used connected cyclers and DaVita's patented technology, DaVita Care Connect®, enabling more convenient access to home treatment data and two-way communication with their care team.
Kidney Smart developed a Home Edition class that expanded its home modality-specific education to further address both HHD and PD modality options.
Learn more about the benefits of home dialysis here.
of home dialysis patients rated DaVita 9 or 10 out of 10
DaVita patients received convenient home dialysis treatments.*
*Modality selections and decisions related to a patient’s care are always made by the attending nephrologist and patient, and provided pursuant to a physician’s order to a physician’s order. Data as of December 31, 2022.
"At DaVita, we believe an informed patient is an empowered patient. Our data show that patients who participate in Kidney Smart classes are more engaged and better equipped to proactively manage their kidney health at every stage and setting of care."
—Dr. Jeff Giullian,
Chief Medical Officer
people participated in a Kidney Smart® class in 2022, another record-setting year of engagement for the no-cost kidney disease education program.
We empower patients to be fully informed about the kidney transplant process, offering resources such as Transplant Smart®, a multi-media patient education program.
More than 99,000 DaVita patients were referred for a transplant at least once by the end of 2022, resulting in the provider's highest referral rate ever.
DaVita patients received a kidney transplant in 2022.
During 2022, DaVita integrated MedSleuth, a transplant software company acquired at the end of 2021, to create greater connectivity among transplant candidates, transplant centers, physicians and care teams, with the aim of improving the experience and outcomes for kidney and liver transplant patients.
We are committed to enabling equity at every step of the kidney care journey. This means reducing and eliminating disparities so that all of our patients, regardless of race, socio-economics or other factors, are empowered with the awareness, education and access needed to achieve their best health outcomes.
Chronic kidney disease disproportionately affects many communities of color, including our Black or African American and Latino or Hispanic patients populations. Sector-wide data demonstrates that too often these disparities continue as patients advance through end-stage kidney disease. We are proud that our patients largely achieve similar outcomes across race in core clinical metrics such as hospitalizations, readmissions and infection rates in our U.S. outpatient dialysis centers. We are continuing to work to reduce other disparities at key journey points.
In 2022 we are proud of:
Launching cultural humility training to patient educators and teams to enable more culturally sensitive and personalized care.
Hearing directly from dialysis patients and caregivers in Black and Mexican American communities across the country through DaVita Clinical Research led focus groups to help us understand the experiences and barriers on the journey to modality choice and transplant.
Integrating MedSleuth, a transplant software company acquired at the end of 2021, that helps improve the transplant experience, including removing barriers to access and supporting patients through the transplant journey.
Read more about health equity from Dr. Jeff Giullian, chief medical officer for DaVita Kidney Care.
Integrated Kidney Care
Through DaVita® Integrated Kidney Care (DaVita IKC), patients receive comprehensive care that goes beyond kidney disease to cover comorbidities and overall health. Our vision is to provide coordinated care to help delay chronic kidney disease (CKD) progression, smooth the transition from CKD to end stage kidney disease (ESKD) and optimize ESKD treatment.
As of December 31, 2022, DaVita IKC provided integrated care and disease management services to approximately 42,000 patients in risk-based integrated care arrangements, and to an additional 15,000 patients in other integrated care arrangements. Learn more about DaVita IKC here.
For more information on our 2022 corporate citizenship initiatives, please visit our ESG Reporting Hub or download our full Community Care ESG Report. Unless otherwise indicated, the data included in this report is as of December 31, 2022 for the Company’s consolidated operations.